Deep Dive Into Nuvation Bio Stock: Analyst Perspectives (7 Ratings)
Benzinga Insights 8 months ago
Analyst Ratings
7 analysts have shared their evaluations of Nuvation Bio (NYSE:NUVB) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $12.57, with a high estimate of $18.00 and a low estimate of $7.00. Marking an increase of 7.71%, the current average surpasses the previous average price target of $11.67.
Exploring Analyst Ratings: An In-Depth Overview
An in-depth analysis of recent analyst actions unveils how financial experts perceive Nuvation Bio. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Yee | UBS | Lowers | Neutral | $7.00 | $10.00 |
| Leonid Timashev | RBC Capital | Raises | Outperform | $13.00 | $12.00 |
| David Nierengarten | Wedbush | Maintains | Outperform | $11.00 | $11.00 |
| Leonid Timashev | RBC Capital | Raises | Outperform | $12.00 | $9.00 |
| Robert Burns | HC Wainwright & Co. | Lowers | Buy | $17.00 | $18.00 |
| Michael Yee | UBS | Announces | Neutral | $10.00 | - |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $18.00 | $10.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Nuvation Bio. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Nuvation Bio compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Nuvation Bio's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Nuvation Bio's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Nuvation Bio analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Nuvation Bio
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Nuvation Bio's Economic Impact: An Analysis
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Nuvation Bio's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1704.68% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Nuvation Bio's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -425.24%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Nuvation Bio's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -15.97%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Nuvation Bio's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.94%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Nuvation Bio's debt-to-equity ratio is below the industry average at 0.18, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: What Are They?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.